Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

The predictive value of mosaic chromosomal alterations for lymphoid malignancies varies by monoclonal B-cell lymphocytosis status

Rosalie Griffin, Tait Shanafelt, Sameer Parikh et al. Nov 03, 2025 pp. 3545-3545 10.1182/blood-2025-3545

Abstract Background Mosaic chromosomal alterations (mCAs) are large-scale somatic gains, losses, or copy-neutral loss of heterozygosity (CNLO...

Pseudo-thrombotic microangiopathy secondary to severe vitamin B12 deficiency: A case series

Ashley Rose, Paul Youn, Lingzhi Liu et al. Nov 03, 2025 pp. 1108-1108 10.1182/blood-2025-1108

Abstract Background: Thrombotic microangiopathy (TMA) is a hematologic emergency classically associated with thrombotic...

The asns inhibitor asx-173 potentiates l-asparaginase anticancer activity

Victor Tatarskii, Wai-kin Chan, Lin Tan et al. Nov 03, 2025 pp. 4327-4327 10.1182/blood-2025-4327

Abstract Background Cancer cells reprogram metabolic pathways to meet increased energy and biosynthetic demands. Among those pathways, eleva...

Targeting adss overcomes venetoclax resistance in TP53-mutated acute myeloid leukemia

Ling Li, Xin He, Lei Zhang et al. Nov 03, 2025 pp. 213-213 10.1182/blood-2025-213

Abstract Venetoclax (VEN), when combined with hypomethylating agents such as azacitidine (AZA), is a critical FDA-approved AML therapy for o...

Acute Myeloid Leukemia mortality in u.S. older adults: A 45-year nationwide analysis with forecasting through 2050

Haseeb Tareen, Allah Dad, Usman Mazhar et al. Nov 03, 2025 pp. 1633-1633 10.1182/blood-2025-1633

Abstract Background: Acute myeloid leukemia (AML) remains a highly fatal hematologic malignancy among older adults in the United States. Des...

Mosunetuzumab (Mosun) or glofitamab (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)

Charalambos Andreadis, Irit Avivi, Neta Goldschmidt et al. Nov 03, 2025 pp. 66-66 10.1182/blood-2025-66

Abstract Background: Mosun and Glofit, both CD20xCD3 T-cell engaging bispecific antibodies, have demonstrated high response rates and manage...

Deepening responses and MRD-conversion in a phase II fixed-duration consolidation trial of elranatamab post-idecabtagene vicleucel CAR-T cell therapy (EPIC) in relapsed or refractory multiple myeloma

Benjamin Puliafito, Matthew Lei, Andrew Yee et al. Nov 03, 2025 pp. 5824-5824 10.1182/blood-2025-5824

Abstract Introduction: Depth of response after idecabtagene vicleucel (ide-cel) CAR-T cell therapy has been correlated with longer progressi...

Formalized transition interventions in adolescents and young adults with sickle cell disease: A study of a transition clinic

Chiamaka Nwachukwu, Melody Benton, Maissaa Janbain et al. Nov 03, 2025 pp. 7891-7891 10.1182/blood-2025-7891

Abstract Background: In the US, adolescents and young adults with sickle cell disease (SCD) are vulnerable to increased mortality due to com...

A multicenter real-world analysis of combined chemotherapy followed by consolidative radiation versus chemotherapy alone in the management of early-stage Hodgkin lymphoma – the HODGKIN25 study

Nikita Dave, Alexandra Dreyfuss, Alison Moskowitz et al. Nov 03, 2025 pp. 3617-3617 10.1182/blood-2025-3617

Abstract Intro Early-stage classical Hodgkin lymphoma (cHL) is a highly curable malignancy. Traditionally, patients (pts) have been treated w...

A tale of two lymphomas: A rare case of transformative post-transplant lymphoproliferative disorder

Alex Holt, Bradley Beeler, Peter Li et al. Nov 03, 2025 pp. 7176-7176 10.1182/blood-2025-7176

Abstract Post-transplant lymphoproliferative disorders (PTLD) are immunodeficiency-related lymphoid proliferations that arise in the setting...

Cytoplasmic but not nuclear cleaved gsdmd expression in live macrophages and DLBCL cells marks proinflammatory cognate interactions rather than pyroptosis and predicts better patient survival in DLBCL

Zijun Xu-Monette, Xue Kong, Zhenming Xu et al. Nov 03, 2025 pp. 7079-7079 10.1182/blood-2025-7079

Abstract Background: Pyroptosis is a form of programmed cell death characterized by cleavage of gasdermin (GSDM) family proteins that form p...

Aplastic anemia treatment in older adults in resource-limited settings: Can rabbit ATG bridge the gap?

Irune Marti Larrucea, Efreen Horacio Montaño Figueroa, Jose Luis Alvarez Vera et al. Nov 03, 2025 pp. 1095-1095 10.1182/blood-2025-1095

Abstract Background The treatment of choice for aplastic anemia (AA) is triple immunosuppressive therapy with horse anti-thymocyte globulin...

Comparative safety and effectiveness of apixaban versus warfarin in antiphospholipid syndrome with chronic kidney disease: A real-world propensity-matched cohort study

Fayaz Khan, Madhu Bhargavi Chandra, Zuhair Alam Nov 03, 2025 pp. 318-318 10.1182/blood-2025-318

Abstract Background: Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by recurrent arterial and/or venous thrombosis...

Rethinking disparity in Acute Myeloid Leukemia, a new perspective in the Asian population

Agomoni Saha, Andriy Derkach, Wenbin Xiao et al. Nov 03, 2025 pp. 38-38 10.1182/blood-2025-38

Abstract Introduction: Racial/ethnic disparities in acute myeloid leukemia (AML) have been increasingly recognized. However, data outside of...

Clonal hematopoiesis of indeterminate potential- a potential risk factor for GI malignancies

Palak Grover, Bipneet Singh, Jahnavi Ethakota et al. Nov 03, 2025 pp. 6697-6697 10.1182/blood-2025-6697

Abstract Introduction Clonal hematopoiesis of indeterminate potential (CHIP) occurs when a hematopoietic stem cell under...

Ruxolitinib for refractory immune effector cell enterocolitis following ciltacabtagene autoleucel CAR T-cell therapy for multiple myeloma

Viktoria Blumenberg, Filippo Birocchi, Angela Shih et al. Nov 03, 2025 pp. 2392-2392 10.1182/blood-2025-2392

Abstract Immune effector cell-associated (IEC)-enterocolitis, characterized by substantial and prolonged diarrhea following B-cell maturatio...

Outcomes of mecom rearranged AML undergoing intensive chemotherapy in the NCRI AML17 and AML19 trials.

Mike Dennis, Jad Othman, Joanna Canham et al. Nov 03, 2025 pp. 3435-3435 10.1182/blood-2025-3435

Abstract Introduction MECOM rearrangements (MECOM::r) account for just 1-2% of adult AML, their outcomes are extremely poor, with high rates...

Efficacy and safety of adjunctive eptifibatide or argatroban versus control for acute ischemic stroke: A systematic review and network meta-analysis of randomized control trials

Teja Sureddi, Haran Srinivasan Saravanan, Noorul Hidhaya S et al. Nov 03, 2025 pp. 1363-1363 10.1182/blood-2025-1363

Abstract Introduction: Acute ischemic stroke is a major cause of disability and mortality, with treatment mainly limited to intravenous alte...

Molecular correlates of response and survival with venetoclax plus hypomethylating agent in treatment-Naïve high-risk myelodysplastic syndrome

Sarvarinder Gill, Shuqi Wang, Jamie Koprivnikar et al. Nov 03, 2025 pp. 7386-7386 10.1182/blood-2025-7386

Abstract Introduction High-risk myelodysplastic syndrome (HR-MDS) remains therapeutically challenging and is associated with poor overall su...

Clinical and biological correlates of blast-transformed chronic myelomonocytic leukemia (CMML): A multicenter study of 493 paired cases at chronic phase and at blast transformation

Clifford Csizmar, Guillermo Montalban-Bravo, Leila Cysique-Foinlan et al. Nov 03, 2025 pp. 2081-2081 10.1182/blood-2025-2081

Abstract Introduction Blast transformation (BT) in CMML occurs in 15-30% of patients (pts) with a median overall survival (OS) <6 mon...

Insights from a multicenter study on the outcomes of liver abscess after allogeneic hematopoietic stem cell transplantation

Fanhao Nie, Hai-Xia Fu, Yuanyuan Zhang et al. Nov 03, 2025 pp. 4267-4267 10.1182/blood-2025-4267

Abstract Introduction: Liver abscess (LA), a severe and potentially life-threatening infection, is characterized by the...

Development of a novel proteomic biomarker for cancer-associated thrombosis

Preeti Preeti, Dang Pham, Mrinal Ranjan et al. Nov 03, 2025 pp. 23-23 10.1182/blood-2025-23

Abstract Introduction Clinical risk assessment scores can help risk-stratify patients for cancer-associated thrombosis (CAT); however, their...

Defective mitophagy of CD4+T cells in ITP via NAD+/SIRT1 reduction

Yu-Xiu Chen, Meng-Yu Xiao, Jian-Ying Zhou et al. Nov 03, 2025 pp. 1247-1247 10.1182/blood-2025-1247

Abstract Introduction Immune thrombocytopenia (ITP), an acquired autoimmune disease, is characterized by immune-mediated platelet destructio...

High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study

Jorge Castillo, Gottfried von Keudell, Andrew Branagan et al. Nov 03, 2025 pp. 225-225 10.1182/blood-2025-225

Abstract Background: BTK inhibitors and BCL2 antagonists, as monotherapy, are highly active and well tolerated in Waldenström macroglobuline...

An echocardiography and ferritin-based screening model to optimise cardiac T2* MRI use for detecting myocardial iron overload in transfusion-dependent thalassemia patients

Rudra Narayan Swain, Nitinkumar Patel, Sarthak Wadhera et al. Nov 03, 2025 pp. 943-943 10.1182/blood-2025-943

Abstract Background: Myocardial iron deposition drives heart failure in transfusion-dependent β-thalassemia major, yet cardiac T2* magnetic...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page